NasdaqGM:URGNBiotechs
UroGen Pharma (URGN) Is Up 14.6% After Phase 3 ENVISION Data And LG-UTUC Outreach Push
In late March and early April 2026, UroGen Pharma announced publication of pivotal Phase 3 ENVISION data for bladder cancer therapy ZUSDURI and launched its “LG-UTUC Luminaries” program to recognize leaders in kidney-sparing care for rare upper tract urothelial cancer.
Together, these steps highlight UroGen’s push to embed ZUSDURI’s evidence into clinical practice while deepening relationships with urologists focused on organ-preserving cancer management.
Next, we’ll examine how the ENVISION...